Vera Therapeutics, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Vera Therapeutics, Inc. (VERA) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $1.91 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2022-11-09
- Vera Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2022-09-30 was $647.00K.
- Vera Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2022-06-30 was $636.00K.
- Vera Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2022-03-31 was $626.00K.
- Vera Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2021-09-30 was $0.00.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month |
|---|---|---|---|
| 2022-09-30 | $647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.28M derived: sum of 2 quarters · filed 2022-11-09 | $1.91M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.26M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $626.00K 10-Q · filed 2022-05-16 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |